Most cases of Cushing syndrome are not inherited from a parent. The vast majority arise from sporadic events, either a tumor that develops its own genetic mutations during a person’s lifetime or, most commonly of all, from taking corticosteroid medications. That said, a meaningful minority of cases do trace back to inherited gene mutations, and the list of these hereditary forms has grown steadily over the past two decades. Understanding where heredity fits into the picture requires sorting through several distinct subtypes, each with its own genetic story.
Why Most Cushing Syndrome Is Not “Genetic” in the Way People Usually Mean
When people ask whether a condition is genetic, they typically want to know if it runs in families or if they could pass it to their children. For Cushing syndrome, the honest answer is: usually not. The single most common cause of Cushing syndrome worldwide is the use of prescription glucocorticoid medications like prednisone, hydrocortisone, or dexamethasone. These drugs suppress the body’s own cortisol-regulating feedback loop, and when used at high doses or for long stretches, they can produce the full clinical picture of Cushing syndrome, including weight gain concentrated around the midsection and face, thinning skin, high blood sugar, and weakened bones.1Journal of Clinical and Translational Endocrinology: Case Reports. Exogenous Cushing’s syndrome secondary to intermittent high dose oral prednisone for presumed asthma exacerbations in the setting of multiple emergency department visits This form is called exogenous Cushing syndrome, and genetics plays no role in it at all. It resolves when the medication is tapered or stopped.
When doctors talk about endogenous Cushing syndrome, the kind where the body itself overproduces cortisol, the picture gets more nuanced. Roughly 80 to 85 percent of endogenous cases are driven by a tumor that secretes ACTH (the hormone that tells the adrenal glands to make cortisol), while the remaining 15 to 20 percent come from the adrenal glands themselves producing cortisol independently of ACTH signals.2The Journal of Clinical Endocrinology & Metabolism. Approach to the Patient: Diagnosis of Cushing Syndrome In both categories, the tumors driving the problem usually arise from mutations that happen spontaneously in a single cell during a person’s lifetime. These are called somatic mutations. They are not present in the person’s DNA at birth and cannot be passed on to children.
Somatic Mutations in Pituitary Tumors
The most common endogenous form, often called Cushing’s disease specifically, involves a small tumor in the pituitary gland that churns out too much ACTH. For decades, researchers knew these tumors existed but could not explain why the pituitary cells went rogue. A major breakthrough came when somatic mutations in a gene called USP8 were identified in a large fraction of ACTH-secreting pituitary tumors, somewhere between 36 and 62 percent depending on the study. These mutations cause the USP8 protein to become hyperactive, which ramps up signaling through a growth-factor receptor and ultimately drives the cell to produce excess ACTH.3PubMed Central. USP8 mutation in Cushing’s disease The key point: these USP8 mutations are found only in the tumor tissue, not in the patient’s blood or other organs. They are acquired, not inherited.
This distinction matters. A person diagnosed with a pituitary ACTH-secreting tumor can generally be reassured that their children are not at elevated risk for the same problem, assuming no other features suggest a familial syndrome. The tumor arose from bad luck at the cellular level, not from a gene variant that was present from conception.
Somatic Mutations in Adrenal Tumors
When Cushing syndrome comes from an adrenal tumor that produces cortisol on its own, bypassing ACTH altogether, the genetic landscape looks different but follows the same principle: the mutations are overwhelmingly somatic. Three independent research groups reported in 2014 that mutations in the PRKACA gene, which encodes the business end of protein kinase A, are found in a substantial proportion of cortisol-producing adrenal adenomas. One group identified PRKACA mutations in about 37 percent of adenomas from patients with overt Cushing syndrome and found that these mutations were absent in patients with milder cortisol overproduction or other adrenal tumor types.4PubMed Central. Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome Another group found a specific hotspot mutation (L205R) in about 65 percent of the cortisol-producing adenomas they examined.5Science. Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome A third confirmed a nearly identical hotspot in over half of their cases.6Science. Recurrent somatic mutations underlie corticotropin-independent Cushing’s syndrome
What all these mutations do is force the enzyme to stay “on” all the time, driving the adrenal cell to keep producing cortisol even when the body’s normal feedback signals are telling it to stop.7PubMed Central. Cushing’s syndrome: from physiological principles to diagnosis and clinical care Again, these mutations are found in the tumor tissue only. They are not inherited and do not run in families.
When Cushing Syndrome Actually Is Inherited
There are, however, genuine hereditary forms. These are uncommon, but they are well documented, and in some cases genetic testing can identify at-risk family members before they develop symptoms. The hereditary forms generally fall into two categories: inherited syndromes that affect multiple organs (with Cushing syndrome as one possible feature) and inherited conditions that primarily target the adrenal glands.
Carney Complex
Carney complex is a rare inherited condition passed down in what geneticists call an autosomal dominant pattern, meaning a single copy of the mutated gene from one parent is enough to cause the condition. People with Carney complex can develop cardiac tumors called myxomas, pigmented skin spots, and a variety of endocrine tumors. One of the hallmark features is a specific adrenal condition called primary pigmented nodular adrenocortical disease (PPNAD), which causes the adrenal glands to develop small, dark nodules that produce cortisol independently.8PubMed. Clinical phenotypes and molecular genetic mechanisms of Carney complex The gene most commonly responsible is PRKAR1A, which encodes the regulatory subunit of the same protein kinase A enzyme that is hit by somatic mutations in sporadic adrenal adenomas. Germline mutations in PRKAR1A are found in roughly 45 percent of all Carney complex patients and in up to 80 percent of those who develop Cushing syndrome from PPNAD.9PubMed. PRKAR1A mutations in primary pigmented nodular adrenocortical disease Some patients with isolated PPNAD, without other Carney complex features, also carry these PRKAR1A mutations.
Multiple Endocrine Neoplasia Type 1
MEN1 is another autosomal dominant syndrome, caused by mutations in the MEN1 gene. It predisposes people to tumors of the parathyroid glands, the pancreas, and the pituitary. In MEN1 patients, Cushing syndrome can arise from a pituitary tumor that overproduces ACTH, from an adrenal tumor, or occasionally from other endocrine tumors.10PubMed Central. Cushing’s Syndrome in Multiple Endocrine Neoplasia Type 1 Cushing syndrome is not the most common feature of MEN1, but when it occurs, the underlying genetic cause is clearly inherited.
Familial Isolated Pituitary Adenomas
Some families develop pituitary tumors without the other features of MEN1 or Carney complex. This condition, called familial isolated pituitary adenoma (FIPA), accounts for a small fraction of pituitary tumor cases. In about 20 percent of FIPA families, mutations in the AIP gene have been identified as the cause. AIP mutations tend to produce large pituitary tumors at an unusually young age, often in teenagers or young adults. While these mutations are most commonly linked to growth-hormone-secreting tumors, they can also cause Cushing’s disease and other pituitary tumor types.11PubMed Central. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene For the remaining FIPA families without AIP mutations, the genetic cause is still unknown.12PubMed. Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context
ARMC5 and Familial Adrenal Hyperplasia
One of the more striking hereditary forms of Cushing syndrome comes from mutations in ARMC5, a gene on chromosome 16. This gene appears to act as a tumor suppressor in the adrenal glands. When one copy is knocked out by a germline mutation (present from birth) and the second copy is lost to a somatic mutation in adrenal tissue, the result is bilateral macronodular adrenal hyperplasia: both adrenal glands develop large nodules that produce cortisol. In a landmark study, ARMC5 mutations were found in tumors from 55 percent of patients with this condition, and in every case, one mutation was inherited and the other was acquired.13PubMed Central. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome
The practical significance of ARMC5 is that it makes bilateral macronodular adrenal hyperplasia one of the most clearly familial forms of Cushing syndrome. Because the germline mutation can be detected in a blood sample, genetic testing allows doctors to screen family members who may carry the same variant. Carriers may not have developed symptoms yet, but long-term monitoring can catch adrenal changes before they lead to full-blown Cushing syndrome.14Journal of International Medical Research. Genetic background and management outcomes in primary bilateral macronodular adrenal hyperplasia: Implications for diagnosis and treatment—A retrospective cohort study Case reports continue to identify new ARMC5 variants in families across different ethnic backgrounds, and the disease shows variable expressivity, meaning that family members with the same mutation may develop symptoms at very different ages or to different degrees.15PubMed Central. First case report of the ARMC5 (c.2692C>T, p.Arg898Trp) variant in a Chinese family with adrenocorticotropic hormone-independent macronodular adrenal hyperplasia
McCune-Albright Syndrome and Mosaic Genetics
McCune-Albright syndrome deserves its own discussion because it occupies an unusual middle ground. It is caused by mutations in the GNAS gene, which controls the same signaling pathway involved in normal cortisol regulation. But these mutations arise after fertilization, during early embryonic development, so only some of the body’s cells carry the change. This makes McCune-Albright a mosaic condition: the mutation is genetic but not inherited from a parent and (except in extraordinary circumstances) not passed to children.16PubMed Central. Neonatal McCune-Albright syndrome with systemic involvement: a case report
The effects depend on which cells carry the mutation. When adrenal tissue is affected, the result can be Cushing syndrome that is independent of ACTH, sometimes appearing in infancy.17Hormone Research in Paediatrics. A Novel GNAS Mutation Causing Isolated Infantile Cushing’s Syndrome Other tissues can be affected too, leading to a combination of bone abnormalities, skin pigmentation, and overactive endocrine glands. Because the mutation is not present in every cell, standard blood-based genetic tests can miss it; sometimes a tissue sample from the affected area is needed to confirm the diagnosis.
Childhood Adrenal Tumors and TP53
In children, adrenocortical tumors are rare but have a surprisingly strong genetic component. A large genomic study of pediatric adrenocortical tumors found that TP53 mutations and loss of the normal copy of chromosome 17 were present in 76 percent of the tumors examined.18PubMed Central. Genomic landscape of paediatric adrenocortical tumours TP53 is one of the most studied genes in cancer biology, acting as a brake on cell growth. When both copies are lost, cells can grow unchecked. In some families, a germline TP53 mutation is inherited, giving rise to a condition known as Li-Fraumeni syndrome, which dramatically raises the risk of multiple cancer types throughout life. In certain regions of the world, specific TP53 variants are remarkably common and account for unusually high rates of childhood adrenal tumors. For a child diagnosed with an adrenocortical tumor, genetic evaluation for TP53 mutations is standard practice, because the implications extend far beyond the adrenal glands.
Ectopic ACTH and Tumors in Unusual Places
Between roughly 5 and 15 percent of endogenous Cushing syndrome cases are caused by tumors outside the pituitary that secrete ACTH on their own.19PubMed Central. A rare case of ectopic ACTH syndrome caused by primary renal neuroendocrine tumor These are most often neuroendocrine tumors found in the lungs, thymus, or pancreas. Ectopic ACTH syndrome tends to present with a rapid, severe onset, and the source of the excess hormone can be frustratingly hard to locate. In some patients, the offending tumor eludes imaging for years.20JCEM Case Reports. The Elusive Neuroendocrine Tumor: Finding the Ectopic ACTH Source 16 Years After the Diagnosis of Cushing Syndrome These tumors are generally sporadic, not inherited, though in rare cases they can arise in the context of inherited cancer-predisposition syndromes.
When Conditions Mimic Cushing Syndrome Without a Tumor
Adding to the complexity, several medical conditions can push cortisol levels high enough to look almost identical to true Cushing syndrome on laboratory tests and even on physical examination. Severe depression, heavy alcohol use, poorly controlled diabetes, extreme obesity, and chronic high-stress states can all activate the body’s cortisol-producing axis to a degree that mimics a tumor-driven problem. These states were historically called “pseudo-Cushing syndrome,” though the preferred term now is physiologic or non-neoplastic hypercortisolism.21PubMed. Differentiation of pathologic/neoplastic hypercortisolism (Cushing’s syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing’s syndrome) Distinguishing these from true Cushing syndrome can be one of the most difficult diagnostic puzzles in endocrinology, and they have no genetic basis in the way inherited tumor syndromes do. Treating the underlying condition typically brings cortisol back to normal.
When Genetic Testing and Family Screening Make Sense
For the large majority of adults diagnosed with Cushing syndrome from a single pituitary or adrenal tumor, genetic testing is not routinely needed. The mutations driving the tumor are somatic and do not affect the rest of the body or the next generation. Genetic evaluation becomes important under specific circumstances:
- Young age at diagnosis: Cushing syndrome appearing in childhood or adolescence raises the suspicion of a germline genetic cause, particularly TP53 mutations, AIP mutations, or Carney complex.
- Bilateral adrenal disease: When both adrenal glands are enlarged and producing excess cortisol, especially with multiple nodules, an inherited mutation in ARMC5 or PRKAR1A should be considered.
- Family history of pituitary tumors: Two or more family members with pituitary tumors of any type point toward FIPA, and AIP testing can guide screening of at-risk relatives.
- Associated features: Skin pigmentation changes, cardiac tumors, bone abnormalities, or tumors in other endocrine glands suggest a syndromic cause like Carney complex, MEN1, or McCune-Albright syndrome.
For families with confirmed ARMC5 mutations, cascade screening of first-degree relatives is increasingly recommended. Because the adrenal changes develop slowly and cortisol excess may be mild for years, early detection through imaging and hormonal testing allows intervention before serious complications take hold.14Journal of International Medical Research. Genetic background and management outcomes in primary bilateral macronodular adrenal hyperplasia: Implications for diagnosis and treatment—A retrospective cohort study
Epigenetic Changes From Excess Cortisol Itself
An emerging area of research looks not at the genetic mutations that cause Cushing syndrome but at how the prolonged high cortisol of Cushing syndrome changes how genes behave in the rest of the body. Cortisol exposure can alter the activity of small regulatory molecules called microRNAs, which help control which genes are turned on or off in a given tissue. Research has found that patients with active Cushing’s disease show altered microRNA patterns in bone tissue, which may help explain why these patients suffer from weakened bones even after cortisol levels are normalized. Similarly, changes in microRNAs related to blood vessel biology have been observed, potentially contributing to the cardiovascular problems that persist in some patients long after their Cushing syndrome is treated.22PubMed Central. Epigenetic Mechanisms Modulated by Glucocorticoids With a Focus on Cushing Syndrome These epigenetic effects are not inherited mutations, but they represent a way that the disease’s consequences may linger at a molecular level even after the source of excess cortisol is gone.
How Dogs Are Helping Researchers Understand Cushing’s Disease
Cushing’s disease from pituitary tumors is not unique to humans. It is actually one of the most common endocrine disorders in older dogs, particularly certain breeds. Researchers have begun comparing the genomic features of pituitary tumors in humans and dogs, finding enough overlap to suggest that canine Cushing’s disease could serve as a natural model for studying the human condition and testing new treatments.23BMC Endocrine Disorders. The genomic profiling and MAMLD1 expression in human and canines with Cushing’s disease Dogs develop these tumors spontaneously, progress through similar clinical stages, and respond to some of the same drugs. This cross-species work is part of a broader push toward targeted therapies, including drugs aimed at the specific receptors and signaling pathways that drive pituitary ACTH-secreting tumors.24PubMed Central. Advances in Molecular Pathophysiology and Targeted Therapy for Cushing’s Disease For patients, the practical takeaway is that the molecular understanding of Cushing’s disease is advancing rapidly, and the growing catalog of genetic and somatic mutations behind it is opening doors to treatments that go beyond surgery alone.